Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Depreciation and Depletion (2021 - 2025)

Historic Depreciation and Depletion for Krystal Biotech (KRYS) over the last 5 years, with Q3 2025 value amounting to $1.4 million.

  • Krystal Biotech's Depreciation and Depletion rose 769.23% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 million, marking a year-over-year decrease of 873.38%. This contributed to the annual value of $6.0 million for FY2024, which is 1983.22% up from last year.
  • As of Q3 2025, Krystal Biotech's Depreciation and Depletion stood at $1.4 million, which was up 769.23% from $1.3 million recorded in Q2 2025.
  • Krystal Biotech's Depreciation and Depletion's 5-year high stood at $1.8 million during Q2 2024, with a 5-year trough of $438000.0 in Q1 2021.
  • In the last 5 years, Krystal Biotech's Depreciation and Depletion had a median value of $1.2 million in 2023 and averaged $1.0 million.
  • As far as peak fluctuations go, Krystal Biotech's Depreciation and Depletion skyrocketed by 14291.5% in 2023, and later crashed by 2777.78% in 2025.
  • Over the past 5 years, Krystal Biotech's Depreciation and Depletion (Quarter) stood at $449000.0 in 2021, then surged by 132.29% to $1.0 million in 2022, then skyrocketed by 44.49% to $1.5 million in 2023, then decreased by 7.3% to $1.4 million in 2024, then increased by 0.21% to $1.4 million in 2025.
  • Its last three reported values are $1.4 million in Q3 2025, $1.3 million for Q2 2025, and $1.4 million during Q1 2025.